The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1270 articles
Budget cuts to Medi-Cal are unraveling healthcare access for Silicon Valley's immigrant communities, leading to service delays, medication reductions, and fears of exposure. From biopsy cancellations to slashed epilepsy drug coverage, real stories reveal the strain. Nonprofits like Latinas Contra Cancer are stepping in amid a $470M Santa Clara County deficit.
Irish broadcaster Kathryn Thomas reveals her eldest daughter Ellie is starting to grasp that her mum is a public figure, amid chats about fame and family. In her new documentary Young Forever: The Death of Ageing?, she explores aesthetics, Botox normalization, peptides, and biohacking for longevity. As a 47-year-old mum, she emphasizes aging as a privilege while focusing on health for her kids' milestones.
Retatrutide, a promising new weight-loss injection, targets three hormone receptors to tackle obesity and diabetes head-on. Clinical trials demonstrate significant weight loss, and experts suggest it may support longevity goals too. Discover how this triple-action therapy stands out in metabolic health.
Researchers at The University of Queensland have uncovered how wasps and frogs produce bradykinin-like peptides that evolved separately from vertebrate versions to trigger pain in predators. These 'evolutionary doppelgängers' derive from toxin genes, overturning decades of scientific assumptions. This discovery highlights convergent evolution in animal defenses.
A new Stanford Medicine study uncovers why GLP-1 receptor agonists may not work as well for some Type 2 diabetes patients: certain genetic variants lead to GLP-1 resistance. Carried by about 10% of the population, these variants result in higher but less effective GLP-1 levels. This could guide faster, personalized treatment switches.
Ozempic isn't just transforming waistlines—it's igniting a surge in hot sauce sales like Tapatío's. As millions embrace GLP-1 drugs, cravings for bold flavors skyrocket, propelling L.A.'s iconic brand into national expansion under new owners Highlander Partners. This is the untold story of family legacy meeting metabolic health trends.
Scientists have uncovered why Ozempic and similar GLP-1 drugs don't work for everyone: genetic variants in the PAM gene cause GLP-1 resistance in about 10% of people. Despite higher GLP-1 levels, these individuals show reduced drug effectiveness in lowering blood sugar. This breakthrough could pave the way for personalized treatment strategies.
New research reveals a hidden genetic reason why Ozempic fails for some: GLP-1 resistance linked to PAM gene variants affecting 10% of the population. Despite higher GLP-1 levels, these individuals show reduced drug efficacy in lowering blood sugar. Discover the study's findings from humans, mice, and clinical trials.
New studies uncover genetic variations in GLP1R and GIPR genes that predict better weight loss and higher side effect risks with GLP-1 drugs like Ozempic and Mounjaro. Cardiac protections from semaglutide appear separate from obesity reduction. A mouse study highlights noncoding DNA mutations' profound developmental impacts.
